The VEGF family of growth factors and its receptors constitute the most important signaling pathways in tumor angiogenesis; therefore, TACE in combination with VEGF inhibitors could be used for further treatment of patients with intermediate or advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.